Cerner Corporation (U.S.), GE Healthcare (U.K.), McKesson Corporation (U.S.), Allscripts Healthcare Solutions Inc. (U.S.), EPIC Systems (U.S.) Are Some of the Leading Players in the Fragmented Healthcare IT Market

In light of the escalating healthcare costs, currently, the North American healthcare industry is increasingly focusing on reducing administrative and clinical expenditure by implementing various healthcare IT tools in their organizations. With the growing demand for simplified data-sharing among various stakeholders in the healthcare industry, majority of the software vendors are focusing on incorporating greater degree of interoperability in their product portfolios. This is one of the key factors driving innovation in the North American healthcare IT market. Clinical healthcare IT solutions (such as EHR/EMR, CPOE, RIS, and CDSS) and non-clinical solutions (such as healthcare analytics and customer relationship management tools) are at the focus of such innovations from vendors in the North American healthcare IT market.

Find Report @ http://www.marketsandmarkets.com/Market-Reports/north-america-healthcare-it-market-1190.html

 

Although, the North American healthcare IT market is highly fragmented in nature with the presence of a number of small and medium-sized vendors operating at local and regional levels; Cerner Corporation (U.S.), GE Healthcare (U.K.), Epic Systems. (U.S.), McKesson Corporation (U.S.), Philips N.V. (Netherlands), and Allscripts Healthcare Solutions, Inc. are some of the leaders in the clinical healthcare IT solutions market. On the other hand, Oracle Corporation (U.S.), Infor, Inc. (U.S.), SAP AG (Germany), and McKesson Corporation (U.S.) are leaders in the non-clinical healthcare IT market. While product innovation remains at the center of the strategic growth initiatives pursued by a majority of the key vendors in the North American healthcare IT market, players are also focusing on increasing their presence in the high-growth markets through the mode of expansions, strategic marketing and distribution agreements, and acquisitions.

Cerner Corporation’s leading position in the clinical solutions market is mainly attributed to its broad product portfolio with major focus on clinical healthcare IT solutions. While nearly 89% of the company’s revenue is attributed to its operations in the North American market, currently, the company is focusing on strengthening its presence through the mode of expansions and agreements. For instance, in February 2015, Cerner Corporation acquired Siemens’s health information technology business unit for ~USD 1.3 billion. This acquisition will strengthen Cerner’s client base in the North America market.

McKesson Corporation offers a wide range of both clinical and non-clinical healthcare IT solutions, which has enabled the company to achieve a leading position in the North American healthcare IT market. The company has major presence in the U.S, and generates a majority of its revenue from North American operations. Similarly, EPIC Systems (U.S.) and Allscripts Healthcare Solutions, Inc. are the leading providers of EHR systems and related solutions in the U.S.

Key Players in the Anti-snoring Treatments Market Pursue New Product Launches and Acquisitions as their Key Growth Strategies

The anti-snoring treatments market is highly fragmented with several global as well as local players. The oral appliances segment dominates the anti-snoring devices market. Some of the key players in the oral appliances market include Sleeping Well, LLC (U.S.), Apnea Sciences Corporation (U.S.), Tomed Dr. Toussaint GmbH (Germany), Sleep Well Enjoy Life, Ltd. (U.K.), and MEDiTAS Ltd. (U.K.). 

Find Report @ http://www.marketsandmarkets.com/Market-Reports/anti-snoring-devices-market-215567849.html

Anti-snoring product manufacturers are focusing on product awareness to gain higher market shares. In order to achieve this, manufacturers are focusing on advertising their products through different channels. Each year, over millions of dollars is spent on the Internet, TV, radio, and print advertisements. According to industry experts, in the past few years, the spending on product advertisement has increased by 25% to 50%. In addition to this, players are focusing on launching new and advanced products. For instance, in October 2013, Airway Management Inc. (U.S.) launched myTAP boil and bite mandibular advancement device (MAD), and in June 2012, Theravent, Inc. (U.S.) launched Theravent Advanced Nightly Snore Therapy.

The key strategies followed by most companies in this market are new product launches, acquisitions, agreements, and expansions. New product launches accounted for the largest share of the overall growth strategies mapped from 2012 to 2015. Apnea Sciences Corporation (U.S.), Sleep Well Enjoy Life Ltd. (U.K.), Airway Management, Inc. (U.S.), Theravent, Inc. (U.S.), and Meditas, Ltd. (U.K.) adopted this strategy.

---

Johnson & Johnson (U.S.), Baxter International Inc. (U.S.) and Medtronic, Inc. (U.S.) Dominate the Biosurgery Market

The biosurgery market is a highly competitive market, with large number of players competing for greater market penetrance and higher market shares. Some of the major players in this market include Johnson & Johnson (U.S.), Baxter International Inc. (U.S.), Sanofi Group (France), Covidien plc (Ireland), Cryolife, Inc. (U.S.), Stryker Corporation (U.S.), and Getinge Group (Sweden).

Report @ http://www.marketsandmarkets.com/Market-Reports/biosurgery-market-166922302.html

Johnson & Johnson (U.S.) led the sealants, hemostatic agents, adhesion barriers, and staple-line reinforcement agents market in 2014. This was majorly attributed to the company’s strong and wide product portfolio and strong presence across the globe, covering North America, Europe, the Middle East and Africa, and Asia-Pacific. The company strongly focuses on introducing new products and gaining regulatory approvals for its products in different markets. The company gained approvals for additional indications for its existing products which strengthened its revenue generation. Moreover, in May 2011, the company launched a new product—ETHICON SECURESTRAP 5mm Absorbable Strap in the U.S., which widened its portfolio for the biosurgery market. Baxter International, Inc. (U.S.) was the second leading company for the sealants, hemostatic agents, adhesion barriers, and staple-line reinforcement agents market in 2014.

Medtronic, Inc. (U.S.) led the bone-graft substitutes market in 2014 owing to its strong product portfolio and significant presence in the demineralized bone matrix (DBM) market. The other leading players in the bone-graft substitute products market include Johnson & Johnson (U.S.), Integra LifeSciences (U.S.), and Stryker Corporation (U.S.).

Mergers and acquisitions, expansions, and new product launches were the key strategies adopted by major players in the biosurgery market from 2011 to 2015. Mergers and acquisitions was the preferred growth strategy during the forecast period, as this strategy enabled greater penetrance of the market through better product offerings.

Edwards Lifesciences Corporation and PULSION Medical Systems SE to dominate the Global Hemodynamic Monitoring System Market

The hemodynamic monitoring systems market has witnessed various technological advancements in the recent years. This can be attributed to the market players focusing on the introduction of newer systems to determine the hemodynamic state of a patient. A number of key players are competing against each other in order to launch new and innovative products aimed at expanding their existing customer base. These key players include Edwards Lifesciences Corporation (U.S.), PULSION Medical Systems SE (Germany), and LiDCO Group plc (U.K.). These players jointly accounted for ~65% of the total hemodynamic monitoring systems market in 2014.  

Find Report @ http://www.marketsandmarkets.com/Market-Reports/hemodynamic-monitoring-systems-market-21684146.html

Edwards Lifesciences Corporation leads the global hemodynamic monitoring systems market. The firm has a wide portfolio in critical care monitoring, heart valves therapy, and hemodynamic monitoring. Its hemodynamic monitoring offerings comprise platforms/monitors, sensors, probes, and catheters. The hemodynamic monitoring devices represented approximately 23%, 26%, and 29% of the company sales in 2013, 2012, and 2011, respectively. The firm focuses on R&D investment to develop noninvasive and minimally invasive hemodynamic monitoring systems. In 2013, the R&D expenditure accounted for 16% ($323 million) of the company’s sales. To sell these developed products, the firm maintains both direct and indirect sales forces. In addition, the firm conducts marketing and sales activities such as educational symposia and customer training to creating awareness of its products and technologies.

PULSION Medical Systems SE is the second-largest player of the hemodynamic monitoring systems market. It offers platforms/monitors, sensors, probes, and catheters for hemodynamic monitoring based on PiCCO technology, ProAQT technology, and CeVOX technology. With a vision to offer its PiCCO technology (and CeVOX technology in some cases) for the development of integrated modular solutions for patient monitoring, the company has partnered with several leading companies in the field of perioperative monitoring such as Philips Healthcare, Dräger Medical, Mindray, and GE Healthcare. The company focuses on R&D activities to cater to the needs of its customers. In 2013, the company invested $3.05 million (6.3% of its revenue) in R&D. The company sells its products in the international markets through its own sales force and joint ventures with local partners. It has distributors located in Africa, Asia, Europe, Australia, North America, Middle East, and South America. In addition, it has built a huge network of scientists, leading clinical experts, and key opinion leaders. This network keeps the company well-informed of the latest market scenario and provides access to new distribution channels. Some of the other prominent strategic moves undertaken by leading players in the hemodynamic monitoring systems market include agreements, partnerships, joint ventures, and collaborations; and geographic expansions. Players entered into agreements, partnerships, joint ventures, and collaborations to enhance their product offerings and to distribute their products. For instance, in January 2014, Deltex Medical plc (U.K.) collaborated with Australia-based Uscom Ltd. for the distribution of USCOM 1A hemodynamic monitor in the U.K. This collaboration strengthened Uscom Ltd.’s presence in the U.K.

The players in this market adopted the strategy of geographic expansions to increase their customer base across geographies. For instance, in October 2013, Deltex Medical plc (U.K.) received FDA approval for its CardioQ-ODM+, thus increasing the company’s customer base in the U.S.

Stryker Corporation (U.S.) and Arthrex, Inc. (U.S.) to secure leadership position in the Global Foot and Ankle Devices Market

The foot and ankle devices market has witnessed various improvements in treatment options in recent years, which can be attributed to market players focusing on the introduction of newer products and treatments for foot and ankle injuries. Through the launch of new products, a number of key players are competing to increase their market shares and expand their existing customer base. Stryker Corporation (U.S.), Arthrex, Inc. (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Smith & Nephew plc (U.K.), and Wright Medical Technology, Inc. (U.S.) are the top five players of this market. These players accounted for ~67% of the total foot and ankle devices market in 2014.

Find Report @ http://www.marketsandmarkets.com/Market-Reports/foot-ankle-devices-market-845.html

Stryker Corporation was the leading player in the foot and ankle devices market, with a share of 22.1% in 2014. The company has been in the market for about 71 years and offers a diversified product portfolio that includes VariAx Foot Locking Plate System, Hoffmann II MRI External Fixation System, Asnis Micro Cannulated Screw System, and T2 Ankle Arthrodesis Nailing System. Stryker strategically focuses on innovation, for which it consistently invests in R&D (USD 614 million (6.3% of sales) in 2014). This helps the company to constantly develop innovative products and technologies such as BIO4, a next-generation viable bone matrix. Stryker focuses on inorganic growth strategies to ensure market growth. For example, it acquired certain assets of Small Bone Innovations, Inc. (SBi), (U.S.) for approximately USD 358 million in September 2014 to enhance its product offerings by adding the Scandinavian Total Ankle Replacement System (STAR Ankle) to its Foot & Ankle product portfolio. The company has strengthened its position in the market on account of its diversified product portfolio and constant focus on R&D and inorganic growth strategies. 

Stryker Corporation was the leading player in the foot and ankle devices market, with a share of 22.1% in 2014. The company has been in the market for about 71 years and offers a diversified product portfolio that includes VariAx Foot Locking Plate System, Hoffmann II MRI External Fixation System, Asnis Micro Cannulated Screw System, and T2 Ankle Arthrodesis Nailing System. Stryker strategically focuses on innovation, for which it consistently invests in R&D (USD 614 million (6.3% of sales) in 2014). This helps the company to constantly develop innovative products and technologies such as BIO4, a next-generation viable bone matrix. Stryker focuses on inorganic growth strategies to ensure market growth. For example, it acquired certain assets of Small Bone Innovations, Inc. (SBi), (U.S.) for approximately USD 358 million in September 2014 to enhance its product offerings by adding the Scandinavian Total Ankle Replacement System (STAR Ankle) to its Foot & Ankle product portfolio. The company has strengthened its position in the market on account of its diversified product portfolio and constant focus on R&D and inorganic growth strategies. 

Arthrex, Inc. held the second-largest share of ~15.6% in 2014. Innovation has helped this company to expand its product portfolio, enter new markets, and build a better network to enhance its customer base. Furthermore, Arthrex focuses on inorganic strategies to ensure market growth. For instance in October 2014, it partnered with Osiris Therapeutics, Inc. (U.S.), a leading cellular and regenerative medicine company, to commercialize and develop Cartiform (Osiris) and receive exclusive commercial distribution rights for the product.

Strategies adopted by players in the foot and ankle devices market include new product launches, agreements, joint ventures, partnerships, acquisitions, and expansion. New product launches was the major growth strategy implemented by companies; it accounted for over 37% of all strategic developments in the market during 2012 to 2015.

Key players that adopted this strategy are Stryker Corporation (U.S.), Arthrex, Inc. (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Smith & Nephew plc (U.K.), Wright Medical Technology, Inc. (U.S.), Integra LifeSciences Holdings Corporation (U.S.), Tornier N.V. (The Netherlands), Össur (Iceland), Acumed, LLC (U.S.), and Extremity Medical, LLC (U.S.).